{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:32:35Z","timestamp":1789551155103,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"DOI":"10.1186\/s13011-024-00631-9","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:22:53Z","timestamp":1739899373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder"],"prefix":"10.1186","volume":"20","author":[{"given":"Laura B.","family":"Monico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Eastlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Michero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton","family":"Pielsticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Glasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"631_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.010","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019. https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.010.","journal-title":"Int J Drug Policy"},{"key":"631_CR2","unstructured":"Anonymous Key Substance Use and Mental Health Indicators in the United States. Results from the 2020 National Survey on Drug Use and Health, October."},{"key":"631_CR3","doi-asserted-by":"crossref","unstructured":"Namchuk AB, Lucki I, Browne CA. Buprenorphine as a treatment for major depression and opioid use disorder. Advances in drug and alcohol research; 2022.","DOI":"10.3389\/adar.2022.10254"},{"key":"631_CR4","doi-asserted-by":"crossref","unstructured":"Carley JA, Oesterle T. Therapeutic approaches to opioid use disorder: what is the current Standard of Care? International Journal of General Medicine; 2021.","DOI":"10.2147\/IJGM.S295461"},{"key":"631_CR5","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ; 2017.","DOI":"10.1136\/bmj.j1550"},{"key":"631_CR6","doi-asserted-by":"crossref","unstructured":"Clark SA, Davis C, Wightman RS, et al. Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island. J Subst Abuse Treat; 2021.","DOI":"10.1016\/j.jsat.2021.108283"},{"key":"631_CR7","doi-asserted-by":"crossref","unstructured":"Madras BK, Ahmad NJ, Wen J, et al. The prevention, treatment, and recovery working group of the action collaborative on countering the US opioid epidemic. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect Discus; 2020.","DOI":"10.31478\/202004b"},{"key":"631_CR8","doi-asserted-by":"crossref","unstructured":"Jones CM, Han B, Baldwin GT, et al. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Network Open; 2023.","DOI":"10.1001\/jamanetworkopen.2023.27488"},{"key":"631_CR9","doi-asserted-by":"crossref","unstructured":"Bresett JW, Kruse-Diehr AJ. Medications for opioid use disorder in rural United States: a critical review of the literature, 2004\u20132021. Subst Use Misuse 2023.","DOI":"10.1080\/10826084.2022.2149244"},{"key":"631_CR10","doi-asserted-by":"crossref","unstructured":"Showers B, Dicken D, Smith JS et al. Medication for opioid use disorder in rural America: a review of the literature. J Rural Mental Health 2021.","DOI":"10.1037\/rmh0000187"},{"key":"631_CR11","doi-asserted-by":"crossref","unstructured":"Gregory HM, Hill VM, Parker RW. Implications of increased access to buprenorphine for medical providers in rural areas: a review of the literature and future directions. Cureus. 2021.","DOI":"10.7759\/cureus.19870"},{"key":"631_CR12","doi-asserted-by":"crossref","unstructured":"Bommersbach T, Justen M, Bunting AM et al. Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: a scoping review. Int J Drug Policy 2023.","DOI":"10.1016\/j.drugpo.2022.103931"},{"key":"631_CR13","doi-asserted-by":"crossref","unstructured":"Huskamp HA, Riedel L, Uscher-Pines L et al. Initiating opioid use disorder medication via telemedicine during COVID-19: implications for proposed reforms to the Ryan Haight Act. Journal of general internal medicine 2022.","DOI":"10.1007\/s11606-021-07174-w"},{"key":"631_CR14","doi-asserted-by":"crossref","unstructured":"Aronowitz SV, Engel-Rebitzer E, Dolan A et al. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Harm reduction journal 2021.","DOI":"10.1186\/s12954-021-00572-7"},{"key":"631_CR15","doi-asserted-by":"crossref","unstructured":"Lin L, Zhang L, Kim HM et al. Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder. Am J Psychiatry 2022.","DOI":"10.1176\/appi.ajp.21111141"},{"key":"631_CR16","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2021.0308","author":"Guillen","year":"2022","unstructured":"Guillen AG, Reddy M, Saadat S, et al. Utilization of Telehealth Solutions for patients with opioid use disorder using buprenorphine: a scoping review. Telemedicine e-Health. 2022. https:\/\/doi.org\/10.1089\/tmj.2021.0308.","journal-title":"Telemedicine e-Health"},{"key":"631_CR17","doi-asserted-by":"crossref","unstructured":"Hailu R, Mehrotra A, Huskamp HA et al. Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic. JAMA network open 2023.","DOI":"10.1001\/jamanetworkopen.2022.52381"},{"key":"631_CR18","doi-asserted-by":"crossref","unstructured":"Haggerty T, Stephens HM, Peckens SA, et al. Telemedicine versus in-person primary care: impact on visit completion rate in a rural Appalachian population. The Journal of the American Board of Family Medicine; 2022.","DOI":"10.3122\/jabfm.2022.03.210518"},{"key":"631_CR19","doi-asserted-by":"crossref","unstructured":"Jones CM, Shoff C, Hodges K et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic. JAMA psychiatry 2022.","DOI":"10.1001\/jamapsychiatry.2022.2284"},{"key":"631_CR20","doi-asserted-by":"crossref","unstructured":"Vakkalanka JP, Lund BC, Ward MM et al. Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: a retrospective cohort study of US veterans. Journal of general internal medicine 2022.","DOI":"10.1007\/s11606-021-06969-1"},{"key":"631_CR21","doi-asserted-by":"publisher","first-page":"205520762412584","DOI":"10.1177\/20552076241258400","volume":"10","author":"LB Monico","year":"2024","unstructured":"Monico LB, Eastlick M, Michero D, Pielsticker P, Glasner S. Feasibility and acceptability of a novel digital therapeutic combining behavioral and pharmacological treatment for opioid use disorder. Digit Health. 2024;10:20552076241258400.","journal-title":"Digit Health"},{"key":"631_CR22","unstructured":"Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. sage; 2006."},{"key":"631_CR23","unstructured":"Scientific Software Development GmbH. ATLAS ti ATLAS ti 2019; 8.4."},{"key":"631_CR24","unstructured":"Tracy SJ. Qualitative research methods: collecting evidence, crafting analysis, communicating impact. Wiley; 2019."},{"key":"631_CR25","doi-asserted-by":"crossref","unstructured":"Conway A, Krawczyk N, McGaffey F et al. Typology of laws restricting access to methadone treatment in the United States: a latent class analysis. Int J Drug Policy 2023.","DOI":"10.1016\/j.drugpo.2023.104141"},{"key":"631_CR26","unstructured":"Bonner E. Patient termination as the ultimate failure of addiction treatment: reframing administrative discharge as clinical abandonment. Journal of Social Work Values and Ethics; 2020."},{"key":"631_CR27","doi-asserted-by":"crossref","unstructured":"Schwartz RP, Kelly SM, Mitchell SG, et al. Patient-centered methadone treatment: a randomized clinical trial. Addiction; 2017.","DOI":"10.1111\/add.13622"},{"key":"631_CR28","doi-asserted-by":"crossref","unstructured":"Knudsen HK, Studts JL. Physicians as mediators of health policy: Acceptance of Medicaid in the context of buprenorphine treatment. The journal of behavioral health services & research; 2019.","DOI":"10.1007\/s11414-018-9629-4"},{"key":"631_CR29","doi-asserted-by":"crossref","unstructured":"Patrick SW, Richards MR, Dupont WD, et al. Association of pregnancy and insurance status with treatment access for opioid use disorder. JAMA network open; 2020.","DOI":"10.1001\/jamanetworkopen.2020.13456"},{"key":"631_CR30","doi-asserted-by":"crossref","unstructured":"Mahmoud H, Naal H, Whaibeh E et al. Telehealth-based delivery of medication-assisted treatment for opioid use disorder: a critical review of recent developments. Curr Psychiatry Rep 2022.","DOI":"10.1007\/s11920-022-01346-z"},{"key":"631_CR31","doi-asserted-by":"crossref","unstructured":"Cole TO, Robinson D, Kelley-Freeman A et al. Patient satisfaction with medications for opioid use disorder treatment via telemedicine: brief literature review and development of a new assessment. Front Public Health 2021.","DOI":"10.3389\/fpubh.2020.557275"},{"key":"631_CR32","doi-asserted-by":"crossref","unstructured":"Wang L, Weiss J, Ryan EB et al. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abuse Treat 2021.","DOI":"10.1016\/j.jsat.2020.108272"},{"key":"631_CR33","doi-asserted-by":"crossref","unstructured":"Cambron C, Gouripeddi R, Facelli JC. Healthcare Provider Reports on Social Determinants of Health in Opioid Treatment. Psych; 2023.","DOI":"10.3390\/psych5010007"},{"key":"631_CR34","doi-asserted-by":"crossref","unstructured":"Gregory HM, Hill VM, Parker RW et al. Implications of increased access to buprenorphine for medical providers in rural areas: a review of the literature and future directions. Cureus. 2021.","DOI":"10.7759\/cureus.19870"},{"key":"631_CR35","doi-asserted-by":"crossref","unstructured":"Molfenter T, Sherbeck C, Zehner M et al. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. Substance abuse treatment, prevention, and policy. 2015.","DOI":"10.1186\/s13011-015-0009-2"},{"key":"631_CR36","doi-asserted-by":"crossref","unstructured":"Hutchinson E, Catlin M, Andrilla CHA, et al. Barriers to primary care physicians prescribing buprenorphine. The Annals of Family Medicine; 2014.","DOI":"10.1370\/afm.1595"},{"key":"631_CR37","doi-asserted-by":"crossref","unstructured":"Stein BD, Sorbero M, Dick AW et al. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA 2016.","DOI":"10.1001\/jama.2016.10542"},{"key":"631_CR38","doi-asserted-by":"crossref","unstructured":"Uscher-Pines L, Sousa J, Raja P et al. Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat 2020.","DOI":"10.1016\/j.jsat.2020.108124"},{"key":"631_CR39","doi-asserted-by":"crossref","unstructured":"Kang AW, Walton M, Hoadley A et al. Patient experiences with the transition to telephone counseling during the COVID-19 pandemic. In: HealthcareAnonymous, pp.663: MDPI.","DOI":"10.3390\/healthcare9060663"},{"key":"631_CR40","doi-asserted-by":"crossref","unstructured":"Uscher-Pines L, Huskamp HA, Mehrotra A. Treating patients with opioid use disorder in their homes: an emerging treatment model. JAMA 2020.","DOI":"10.1001\/jama.2020.3940"},{"key":"631_CR41","doi-asserted-by":"crossref","unstructured":"Moore DJ, Goyal D, Rodriguez L. Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program. J Addictions Nurs 2021.","DOI":"10.1097\/JAN.0000000000000419"},{"key":"631_CR42","unstructured":"Anonymous SAMHSA, DEA Virtual Town Hall. accessed May 21, Expanding Buprenorphine Access in Pharmacies to Treat Opioid Use Disorder. https:\/\/www.samhsa.gov\/sites\/default\/files\/virtual-town-hall-buprenorphine-access-pharmacies.pdf (2024)."}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-024-00631-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-024-00631-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-024-00631-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:23:08Z","timestamp":1739899388000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-024-00631-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1186\/s13011-024-00631-9","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethical and Independent Review Services\u2019 Institutional Review Board monitored and reviewed this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors are employees of the digital therapeutic company that delivered the virtual care in the larger pilot study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}